travoprost s.k.
k.s.kim international (sk- pharma) ltd., israel - travoprost - ophthalmic solution - travoprost 0.04 mg/ml - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication
apo-travoprost solution
apotex inc - travoprost - solution - 0.003% - travoprost 0.003% - prostaglandin analogs
teva-travoprost z ophthalmic solution
teva canada limited - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs
sandoz travoprost solution
sandoz canada incorporated - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs
apo-travoprost z solution
apotex inc - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs
mylan-travoprost z solution
mylan pharmaceuticals ulc - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs
travatan z- travoprost solution
physicians total care, inc. - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost 0.04 mg in 1 ml - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. none pregnancy category c teratogenic effects: travoprost was teratogenic in rats, at an intravenous (iv) dose up to 10 mcg/kg/day (250 times the maximal recommended human ocular dose (mrhod), evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, such as fused sternebrae, domed head and hydrocephaly. travoprost was not teratogenic in rats at iv doses up to 3 mcg/kg/day (75 times the mrhod), or in mice at subcutaneous doses up to 1 mcg/kg/day (25 times the mrhod). travoprost produced an increase in post-implantation losses and a decrease in fetal viability in rats at iv doses > 3 mcg/kg/day (75 times the mrhod) and in mice at subcutaneous doses > 0.3 mcg/kg/day (7.5 times the mrhod). in the offspring of female rats that received travoprost subcutaneously from day 7 of preg
travatan z- travoprost solution/ drops
alcon laboratories, inc - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost 0.04 mg in 1 ml - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. none. risk summary there are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. in animal reproduction studies, subcutaneous (sc) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. advise pregnant women of a potential risk to a fetus. because animal reproductive studies are not always predictive of human response, travatan z should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is
travoprost/timolol zentiva 40 mikrogramm/ml + 5 mg/ml augentropfen, lösung
duotrav
novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - ophthalmologicals - decrease of intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.